Table 3. Outcomes after repeat CRS/HIPEC for appendiceal primaries.
| Author (citation) | Study type | Year | N | PCI | High grade | Overall survival | PFS | Median follow-up (months) | Morbidity (grade 3 and 4) | Mortality | CC 0-1 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Esquivel et al. (17) | R | 2001 | 98 | NA | NA | 5-year 73.6% | NA | NA | NA | NA | 68.4% (2nd CRS) |
| Yan et al. (18) | R | 2007 | 98 | 19.0 (mean) | 38.0% | 5-year 90.0% | 5-year 70% | 66.0 | NA | NA | 78.0% (2nd CRS) |
| Mohamed et al. (19) | R | 2003 | 45 | NA | 5.0% | 5-year 70.0% | NA | NA | 11.0% | 4.4% | 57.8% (3rd CRS) |
| Miner et al. (20) | R | 2005 | 38/97 | NA | 48.0% | Median survival 9.8 years | NA | NA | 16.0% (of all operations) | 4.0% (entire population) | 35.0% (overall) |
| Sardi et al. (21) | R | 2013 | 26 | >20.0 (65%) | 61.5% | 5-year 33.9 months | NA | 28.0 | 27.0% | 0.0% | 96.0% |
| Votanopoulos et al. (10) | R | 2012 | 33/62 | 9.2 (mean) | 15.2% | Median survival 52.1 months (after 2nd) | NA | 60.8 | 14.5% | 3.2% | R0-R1 43.5%; R2a 25.8%; R2b-R2c 30.6% |
CRS, cytoreductive surgery; HIPEC, hyperthermic intraperitoneal chemotherapy; R, retrospective; N, number of patients; PCI, peritoneal cancer index; PFS, progression free survival; CC, completeness of cytoreduction; NA, not available.